Replies to post #144934 on Amarin Corp Plc (AMRN)

[Pyrrhonian]

B,

I don’t know, but for some reason these generics producers don’t seem to think it will hold up. And if it really is that strong and should prevent anyone until 2042, why agree with Teva to sell by 2029?

I’ve seen this before, and there often seems to be some loophole. Maybe nothing comes of it, but apparently there is something that has them pursuing coming to market, and so they must believe they have a good shot. And it even caused Teva to only agree to 2029 on the contingency they don’t come to market. That is significant to my mind.

But there is one thing I forgot—they’ll get an extension of exclusivity from FDA for 3 years with the new label. It’s called “OSC” or other significant changes exclusivity. So late 2021 or early 2022.

[Biobillionair]

Baa-Amarin has a patent fortress, its not just one patent that protects Vascepa. These patents have been through numerous prior legal challenges both TEVA and AZN eventually succumbed to these actions.

Now the likelihood of another omega fatty acid claiming cardiovascular risk reduction, in a patented formula, is NEXT TO ZERO!


---BB